Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine
Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine
复制标题
诺如病毒 GII.17 病毒样颗粒疫苗的免疫原性和保护效力
DOI：
10.1007/s10529-020-02837-w
复制
发表时间：
2020-02-22
影响因子：
2.7
通讯作者：
Jing, Shenrong
中科院分区：
文献类型：
--
作者：
Chen, Wei;Kang, Tao;Jing, Shenrong
目的：诺如病毒(NOV)是世界范围内急性病毒性胃肠炎的主要致病因素，而病毒样颗粒(VLP)是一种有效的疫苗研制方法。材料和方法：本研究利用重组杆状病毒系统和唾液结合阻断试验检测病毒样颗粒(VLP)在昆虫细胞中的表达，并用唾液结合阻断试验检测其保护力。结果：成功地在sf9昆虫细胞中产生了GII 17 VLP。电子显微镜显示，GII·17VLP呈球形，直径为-35 nm。用纯化的VLP免疫小鼠可产生GII.17特异性血清，并能有效阻断GII.17 VLP与唾液组织血型抗原(HBGA)的结合。结论：这些结果表明，GII.17 VLP是一种很有前途的疫苗候选疫苗，为进一步的临床前和临床研究提供了有力的支持。
Objectives:Noroviruses (NoVs) are major cause of acute viral gastroenteritis in worldwide, and the lack of a cell culture system that must be considered the virus like particles (VLPs) are used as an effective vaccine development.Materials and methods:In the present study, we investigated the expression of the major capsid protein (VP1) of the Genogroup II, genotype 17 (GII.17) NoV, using recombinant baculovirus system in insect cells, as well as a saliva binding blockade assay to detect their protective potency.Results:Our results showed that GII.17 VLPs could be successfully generated in sf9 insect cells, and electron microscopic revealed that GII.17 VLPs appeared as spherical particles with a - 35 nm diameter. Immunized mice with purified VLPs produced GII.17 specific sera and could efficiently block GII.17 VLPs binding to the saliva histo-blood group antigens (HBGAs).Conclusions:Together, these results suggested that GII.17 VLPs represent a promising vaccine candidate against NoV GII.17 infection and strongly support further preclinical and clinical studies.